Pacific Biosciences Of California, Inc. (PACB) · Nov 4, 2026 · Earnings

PacBio earnings miss as margins fall and CFO exits

Miss — Revenue $40.6M vs ~$43.82M consensus

PacBio earnings show modest revenue growth, but a consensus miss, lower margins, falling Revio pull-through and a CFO departure complicate the SPRQ-Nx growth story.

PacBio is trying to turn its HiFi long-read sequencing platform into a higher-utilization clinical, population-genomics and AI data business, with SPRQ-Nx intended to lower sequencing costs and expand Revio adoption. That strategy was already established before this report.

The quarter missed the top-line bar. Revenue rose 5.5% year over year to $40.6 million, but came in roughly 7% below the published consensus of $43.82 million. That is a meaningful shortfall for a company whose 2026 plan depends on a second-half acceleration.

MetricQ3 2026Q3 2025Consensus
Revenue (Financial Highlights)$40.6M (+5.5%)$38.4M$43.82M
Non-GAAP EPS (Reconciliation)$(0.11)$(0.12)$(0.126)
Non-GAAP gross margin (Reconciliation)36%42%
Non-GAAP operating expense (Reconciliation)$47.0M (-12.8%)$53.9M
Revio placements (Financial Highlights)1513
Revio pull-through (Financial Highlights)~$204K (-13.6%)~$236K
Cash and investments (Balance Sheet)$199.4M$298.7M

The core utilization signal is weaker than the placement count suggests. PacBio placed 15 Revio systems versus 13 a year ago, and 35 Vega systems versus 32, but annualized Revio consumables pull-through fell to approximately $204,000 from $236,000. That means the installed base is growing without yet producing the recurring consumables acceleration the SPRQ-Nx strategy needs. The filing says more than half of Revio consumables revenue was tied to SPRQ-Nx and two-thirds of the installed base had opted into the software upgrade, so adoption is real, but the financial conversion remains unproven.

Margin pressure offset the cost-cutting progress. Non-GAAP gross margin fell to 36% from 42%, primarily because of higher memory costs and Vega manufacturing transition costs. Lower personnel expenses reduced non-GAAP operating costs to $47.0 million from $53.9 million, helping non-GAAP EPS beat the loss consensus narrowly, but that improvement came from restructuring rather than stronger operating leverage. 〔0〕 〔1〕

The balance sheet leaves less room for execution error. Cash, cash equivalents and investments fell to $199.4 million from $298.7 million a year earlier, while convertible senior notes remained approximately $643 million. The company is still funding a loss-making transition while its revenue growth remains modest and its recurring usage metric is moving in the wrong direction.

The CFO departure adds execution uncertainty. Jim Gibson stepped down as CFO, with Mark Van Oene taking the interim CFO role and Bill Meyer becoming CAO while PacBio searches for a permanent replacement. 〔2〕

Bottom line: PacBio is making visible progress on placements, SPRQ-Nx adoption and expense control, but the quarter did not yet validate the growth model: revenue missed, margins deteriorated and Revio utilization declined. The CFO transition makes an already demanding execution phase more complicated.

What to watch next

Q4 earnings and 2026 revenue outlook update

Original filing on SEC EDGAR

PacBio earnings miss as margins fall and CFO exits | PACB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.